Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Future drug treatment of Type 1 diabetes

Larsson, Helena LU orcid ; Delli, Ahmed LU ; Ivarsson, Sten LU and Lernmark, Åke LU orcid (2010) p.1001-1016
Abstract
Insulin replacement therapy is considered the only effective and feasible treatment for type 1 diabetes mellitus (T1DM) as only insulin is capable

of reversing the metabolic disturbances and restoring a near - normal quality of life in patients with T1DM. Despite rigorous measures and major advances in health care provided for patients with T1DM, increased morbidity and mortality are still common from complications, which commonly develop within 10 – 12 years after clinical onset.

Advances in the understanding of the natural history of T1DM and increased abilities to predict the disease have made it possible to

design and implement prevention and intervention clinical trials. Clinical trials are aimed at: (a)... (More)
Insulin replacement therapy is considered the only effective and feasible treatment for type 1 diabetes mellitus (T1DM) as only insulin is capable

of reversing the metabolic disturbances and restoring a near - normal quality of life in patients with T1DM. Despite rigorous measures and major advances in health care provided for patients with T1DM, increased morbidity and mortality are still common from complications, which commonly develop within 10 – 12 years after clinical onset.

Advances in the understanding of the natural history of T1DM and increased abilities to predict the disease have made it possible to

design and implement prevention and intervention clinical trials. Clinical trials are aimed at: (a) preventing the initiation of islet

autoimmunity (primary prevention);(b)reducing autoimmune β-cell killing and progression to clinical diabetes (secondary prevention); or(c)suppressing or modulating the immune response in order to halt β-cell killing and enhance β-cell regeneration (tertiary prevention or intervention).

Several trials were implemented or are currently ongoing with dietary manipulation, parenteral or oral insulin or immune-suppressing or immune-modulating agents with the aim of preventing the disease or retarding its progression. The search for safe, effective and feasible drugs to prevent or cure T1DM is still ongoing. So far, immune modulation with alum - formulated GAD65 has been shown to be the most promising intervention to

reduce the loss of β-cells. Anti-CD3 monocloncal autoantibodies also showed some benefits in patients with newly diagnosed T1DM. (Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Chapter in Book/Report/Conference proceeding
publication status
published
subject
host publication
Textbook of Diabetes
editor
Holt, Richard I. G. ; Cockram, Clive S. ; Flyvbjerg, Allan and Goldstein, Barry J.
pages
1001 - 1016
publisher
Wiley-Blackwell
external identifiers
  • scopus:84885968799
ISBN
9781405191814
DOI
10.1002/9781444324808
language
English
LU publication?
yes
id
f4bf09ee-dd73-4de3-9fbf-cc8412759ab8 (old id 3953446)
date added to LUP
2016-04-04 11:41:14
date last changed
2024-10-13 13:24:56
@inbook{f4bf09ee-dd73-4de3-9fbf-cc8412759ab8,
  abstract     = {{Insulin replacement therapy is considered the only effective and feasible treatment for type 1 diabetes mellitus (T1DM) as only insulin is capable <br/><br>
of reversing the metabolic disturbances and restoring a near - normal quality of life in patients with T1DM. Despite rigorous measures and major advances in health care provided for patients with T1DM, increased morbidity and mortality are still common from complications, which commonly develop within 10 – 12 years after clinical onset.<br/><br>
Advances in the understanding of the natural history of T1DM and increased abilities to predict the disease have made it possible to <br/><br>
design and implement prevention and intervention clinical trials. Clinical trials are aimed at: (a) preventing the initiation of islet <br/><br>
autoimmunity (primary prevention);(b)reducing autoimmune β-cell killing and progression to clinical diabetes (secondary prevention); or(c)suppressing or modulating the immune response in order to halt β-cell killing and enhance β-cell regeneration (tertiary prevention or intervention). <br/><br>
Several trials were implemented or are currently ongoing with dietary manipulation, parenteral or oral insulin or immune-suppressing or immune-modulating agents with the aim of preventing the disease or retarding its progression. The search for safe, effective and feasible drugs to prevent or cure T1DM is still ongoing. So far, immune modulation with alum - formulated GAD65 has been shown to be the most promising intervention to <br/><br>
reduce the loss of β-cells. Anti-CD3 monocloncal autoantibodies also showed some benefits in patients with newly diagnosed T1DM.}},
  author       = {{Larsson, Helena and Delli, Ahmed and Ivarsson, Sten and Lernmark, Åke}},
  booktitle    = {{Textbook of Diabetes}},
  editor       = {{Holt, Richard I. G. and Cockram, Clive S. and Flyvbjerg, Allan and Goldstein, Barry J.}},
  isbn         = {{9781405191814}},
  language     = {{eng}},
  pages        = {{1001--1016}},
  publisher    = {{Wiley-Blackwell}},
  title        = {{Future drug treatment of Type 1 diabetes}},
  url          = {{http://dx.doi.org/10.1002/9781444324808}},
  doi          = {{10.1002/9781444324808}},
  year         = {{2010}},
}